Figure 3 :The prevalence of ARD patients after using
anti-rheumatic drugs from the perspective of the main drugs. (A) GC, (B)
bDMARDs, (C) csDMARDs, (D) anti-TNF therapy.
From the perspective of the primary drugs, the prevalences of SLE
patients mainly using GC and csDMARDs were 0.101(95%CI:0.035-0.166) and
0.095(95%CI:0.041-0.149), respectively, using GC had a higher
prevalence and using csDMARDs had a lower prevalence. The prevalence of
vasculitis patients using GC was 0.081(95%CI:0.005-0.157), and using
bDMARDs and csDMARDs were both 0.047(95%CI:-0.021 to 0.114),
respectively, using GC have the highest prevalence. The prevalence of AS
patients using bDMARDs was 0.074(95%CI:0.039-0.108). Due to the small
number of studies and the limitations of statistical methods, the
prevalences of RA patients using bDMARDs and csDMARDs were both
0.028(95%CI:0.019-0.037). Besides, The prevalence of PsA patients using
bDMARDs was 0.289(95%CI:-0.099 to 0.677), suggesting the prevalence in
PsA was not statistically significant(Figure p7).